权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a discovery platform based on microfluidics and fluorescent cell f

开发基于微流体和荧光细胞的发现平台

基本信息

批准号：
8125967
负责人：
BENJAMIN M BUEHRER
金额：
$ 35万
依托单位：
NIVARTA, INC.
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-15 至 2013-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8125967
关键词：
Adipocytes Adipose tissue Biological Assay Cell Culture System Cell Culture Techniques Cell Survival Cells Chemicals Development Devices Diabetes Mellitus Diagnostic Dimensions Disease Dose Drug Costs Fluorescence Genetic Transcription Glass Glucose Goals Growth Human Human Resources Image Insulin Label Libraries Liquid Chromatography Malignant Neoplasms Marketing Methods Microfluidics Microscope Molecular Obesity Patients Pharmaceutical Preparations Plasma Proteins Proteome Radioactive Radiolabeled Reagent Research Personnel Risk Robotics Safety Screening procedure Slide Technology Testing Therapeutic Time Tritium Tube Vial device base biochip cost cost effective culture plates design diabetes management glucose analog glucose uptake high throughput screening high throughput technology meetings nervous system disorder novel novel therapeutics radiotracer response small molecule small molecule libraries

项目摘要

DESCRIPTION (provided by applicant): The overall goal of the project is to develop discovery platform based on microfluidics and functional cell assays that is suitable for screening hundreds of proteins or small-molecule compounds simultaneously in a cost-effective and high throughput manner. The projects Specific Aims are: (1) To develop a microfluidic-based platform for high-throughput screening of potential protein and small molecule therapeutics. (2) To develop an insulin stimulated glucose uptake assay in differentiated 3T3-L1 adipocytes using fluorescent 2-deoxy glucose (2-DOG) analog. (3) To integrate and perform a functional 2-DOG uptake assay in the microfluidics based multi-well cell culture biochip. The deliverable from this completed project is a cost-effective microfluidics based platform suitable for high throughput screening of proteins and small molecule therapeutic compounds. PUBLIC HEALTH RELEVANCE: The long term objective of the project is to identify protein and small molecule therapeutics to treat diseases such as diabetes, obesity, cancer and neurological disorders. As a first step towards this objective, a platform based on microfluidics technology and functional cell bioassays is being developed to screen the entire human proteome and small molecule libraries in a cost-effective and time saving manner. Presently, safety and efficacy of most of the drugs in the market is still a primary concern. However, with more therapies becoming available, it is possible that not only safety standards will be met but also the cost of drugs will be lowered.

描述（由申请人提供）：该项目的总体目标是开发基于微流体和功能细胞检测的发现平台，适合以经济高效和高通量的方式同时筛选数百种蛋白质或小分子化合物。该项目的具体目标是：（1）开发一个基于微流体的平台，用于高通量筛选潜在的蛋白质和小分子疗法。 (2) 使用荧光 2-脱氧葡萄糖 (2-DOG) 类似物开发分化的 3T3-L1 脂肪细胞中胰岛素刺激的葡萄糖摄取测定法。 (3) 在基于微流控的多孔细胞培养生物芯片中集成并执行功能性2-DOG摄取测定。该已完成项目的成果是一个经济高效的基于微流体的平台，适用于蛋白质和小分子治疗化合物的高通量筛选。公共健康相关性：该项目的长期目标是确定蛋白质和小分子疗法来治疗糖尿病、肥胖、癌症和神经系统疾病等疾病。作为实现这一目标的第一步，我们正在开发一个基于微流体技术和功能细胞生物测定的平台，以经济有效且节省时间的方式筛选整个人类蛋白质组和小分子库。目前，市场上大多数药物的安全性和有效性仍然是首要关注的问题。然而，随着更多疗法的出现，不仅可以满足安全标准，而且药物成本也可能会降低。